Phase I/II Trial of Tivantinib With FOLFOX for the Treatment of Advanced Solid Tumors and Previously Untreated Metastatic Adenocarcinoma of the Distal Esophagus, Gastroesophageal Junction or Stomach
- Conditions
- Gastroesophageal CancerMalignant Solid Tumour
- Interventions
- Drug: FOLFOX
- First Posted Date
- 2012-06-05
- Last Posted Date
- 2016-11-23
- Lead Sponsor
- SCRI Development Innovations, LLC
- Target Recruit Count
- 49
- Registration Number
- NCT01611857
- Locations
- 🇺🇸
Yale University School of Medicine, New Haven, Connecticut, United States
🇺🇸Florida Cancer Specialists-Sarasota, Sarasota, Florida, United States
🇺🇸Florida Cancer Specialists-North, St. Petersburg, Florida, United States
Trial of Eribulin/Cyclophosphamide or Docetaxel/Cyclophosphamide as Neoadjuvant Therapy in Locally Advanced HER2-Negative Breast Cancer
- Conditions
- HER2 Negative Breast Cancer
- Interventions
- First Posted Date
- 2012-02-07
- Last Posted Date
- 2016-11-04
- Lead Sponsor
- SCRI Development Innovations, LLC
- Target Recruit Count
- 76
- Registration Number
- NCT01527487
- Locations
- 🇺🇸
Woodlands Medical Specialists, Pensacola, Florida, United States
🇺🇸Nebraska Methodist Cancer Center, Omaha, Nebraska, United States
🇺🇸Northeast Georgia Medical Center, Gainesville, Georgia, United States
Non Small Cell Lung Cancer Patients Treated With Erlotinib Six Months or Longer
- Conditions
- Non Small Cell Lung Cancer
- First Posted Date
- 2012-02-01
- Last Posted Date
- 2016-03-07
- Lead Sponsor
- SCRI Development Innovations, LLC
- Target Recruit Count
- 27
- Registration Number
- NCT01522833
- Locations
- 🇺🇸
Tennessee Oncology, PLLC, Nashville, Tennessee, United States
Study of the Combination of Panobinostat and Carfilzomib in Patients With Relapsed/Refractory Multiple Myeloma
- First Posted Date
- 2011-12-21
- Last Posted Date
- 2022-02-02
- Lead Sponsor
- SCRI Development Innovations, LLC
- Target Recruit Count
- 80
- Registration Number
- NCT01496118
- Locations
- 🇺🇸
Florida Cancer Specialists South, Fort Myers, Florida, United States
🇺🇸Tennessee Oncology-Chattanooga, Chattanooga, Tennessee, United States
🇺🇸Tennessee Oncology, Nashville, Tennessee, United States
A Trial of Single Agent Axitinib as Maintenance Therapy for Patients With First Line Metastatic Colorectal Cancer (mCRC)
- Conditions
- Colorectal Cancer
- Interventions
- First Posted Date
- 2011-12-13
- Last Posted Date
- 2019-09-24
- Lead Sponsor
- SCRI Development Innovations, LLC
- Target Recruit Count
- 70
- Registration Number
- NCT01490866
- Locations
- 🇺🇸
Nebraska Methodist Hospital, Omaha, Nebraska, United States
🇺🇸NEA Baptist Clinic, Jonesboro, Arkansas, United States
🇺🇸Atlantic Health System, Summit, New Jersey, United States
Trial of Erlotinib and BKM120 in Patients With Advanced Non Small Cell Lung Cancer Previously Sensitive to Erlotinib
- First Posted Date
- 2011-12-07
- Last Posted Date
- 2019-03-06
- Lead Sponsor
- SCRI Development Innovations, LLC
- Target Recruit Count
- 37
- Registration Number
- NCT01487265
- Locations
- 🇺🇸
Florida Cancer Specialists South, Fort Myers, Florida, United States
🇺🇸Oncology Hematology Care, Inc., Cincinnati, Ohio, United States
🇺🇸Florida Cancer Specialists East, West Palm Beach, Florida, United States
Study of Hsp90 Inhibitor AUY922 for the Treatment of Patients With Refractory Gastrointestinal Stromal Tumor
- First Posted Date
- 2011-07-28
- Last Posted Date
- 2016-10-04
- Lead Sponsor
- SCRI Development Innovations, LLC
- Target Recruit Count
- 25
- Registration Number
- NCT01404650
- Locations
- 🇺🇸
Florida Cancer Specialists-South, Ft. Myers, Florida, United States
🇺🇸Yale School of Medicine, New Haven, Connecticut, United States
🇺🇸Florida Hospital Cancer Institute, Orlando, Florida, United States
Trial of Eribulin in Patients Who Do Not Achieve Pathologic Complete Response (pCR) Following Neoadjuvant Chemotherapy
- First Posted Date
- 2011-07-26
- Last Posted Date
- 2018-06-15
- Lead Sponsor
- SCRI Development Innovations, LLC
- Target Recruit Count
- 127
- Registration Number
- NCT01401959
- Locations
- 🇺🇸
The Center for Cancer and Blood Disorders, Fort Worth, Texas, United States
🇺🇸Mercy Hospital, Portland, Maine, United States
🇺🇸Texas Health Physician Group, Arlington, Texas, United States
Combination of BKM120 and Bevacizumab in Refractory Solid Tumors and Relapsed/Refractory Glioblastoma Multiforme
- First Posted Date
- 2011-05-06
- Last Posted Date
- 2020-06-17
- Lead Sponsor
- SCRI Development Innovations, LLC
- Target Recruit Count
- 88
- Registration Number
- NCT01349660
- Locations
- 🇺🇸
Tennessee Oncology, Nashville, Tennessee, United States
🇺🇸Yale School of Medicine, New Haven, Connecticut, United States
🇺🇸Center for Cancer and Blood Disorders, Bethesda, Maryland, United States
Study of PI3 Kinase/mTOR Inhibitor BEZ235 Twice Daily for Advanced Solid Tumors
- First Posted Date
- 2011-04-28
- Last Posted Date
- 2015-05-01
- Lead Sponsor
- SCRI Development Innovations, LLC
- Target Recruit Count
- 33
- Registration Number
- NCT01343498
- Locations
- 🇺🇸
Tennessee Oncology, Nashville, Tennessee, United States
🇺🇸Oklahoma University, Oklahoma City, Oklahoma, United States